MedTrace Logo

The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers

NCT03247140 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-12-26

No results posted yet for this study

Summary

The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers

Conditions

  • Hypertension With Dyslipidemia

Interventions

DRUG

JLP-1401

Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)

DRUG

Telmisartan/Amlodipine, Rosuvastatin

Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)

Sponsors & Collaborators

  • Jeil Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Min Gul Kim, MD., Ph.D · Chonbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-10
Primary Completion
2017-08-07
Completion
2017-11-27

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03247140 on ClinicalTrials.gov